Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951988 · ClinicalTrials.gov registry record · Phase 3
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,304
- Enrollment target
NCT02951988 is a Phase 3 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 1,304 participants.
The verdict
NCT02951988, a Phase 3 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,304 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).
Interventions
- DRUG Rapastinel
- DRUG Placebo-matching Rapastinel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,304 participants |
| Start Date | 2016-11-13 |
| Est. Completion | 2019-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02951988
The ClinicalTrials.gov registry entry for NCT02951988 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rapastinel is the first listed.
NCT02951988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02951988 about?
NCT02951988 is a clinical study titled "A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder". This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Di...
What is the current status of trial NCT02951988?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,304 participants. The study started on 2016-11-13. Estimated completion is 2019-02-22.
What interventions are being tested in trial NCT02951988?
The interventions under investigation include: Rapastinel (DRUG), Placebo-matching Rapastinel (DRUG).
Who is sponsoring clinical trial NCT02951988?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.